A methodology read for the next twelve months in B2B peptides.
FDA closed compounding discretion on semaglutide in May 2025. The 2026 rulemaking is the next shoe. Fifty-plus warning letters went out in September 2025 to operators in your neighborhood. The firms that come out the other side will have one thing in common: a methodology layer behind every trust claim. This is a read on what that layer looks like for a B2B peptide channel.
The peptide therapeutics market is on a 7.5 percent CAGR through 2033, headed from forty-six billion to ninety-two billion. The GLP-1 receptor-agonist market is on a 12.4 percent CAGR through the same horizon, headed for one hundred eighty-five billion. The category is real and it is growing.
The non-traditional channel that emerged during the 2022-to-2025 shortage is a different story. The FDA resolved the semaglutide shortage on February 21, 2025. Compounding wind-down dates landed on April 22 for 503A facilities and May 22 for 503B. Tirzepatide compounding discretion ended in March. In September the FDA issued warning letters to more than fifty GLP-1 compounders, telehealth firms, and overseas suppliers. In May 2026 the agency proposed rulemaking that would permanently close the 503B bulks pathway for semaglutide, tirzepatide, and liraglutide. The compounded GLP-1 wholesale lane is on a clock.
Two things are simultaneously true. The peptide channel is a long-term asset. The semaglutide-led storefront has twelve months to restructure around verifiable trust assets, a documented partner facility, and a product mix that does not require regulatory discretion to operate. This read is about the methodology layer that holds during that restructuring.
The framing comes from a methodology called ICM. It says any operation breaks into three layers and most firms waste budget by treating them as one. Sixty percent is database and code that has existed for thirty years. Thirty percent is rule-based logic that a small set of tested rules handles better than any language model. Ten percent is genuine agentic work where probabilistic systems pay off. Three architectures, not one strategy.
In a regulated B2B peptide channel, the sixty-percent layer is the order, batch, and documentation database that downstream HCP buyers will eventually request. The thirty-percent layer is HCP licensure verification, formulary intake routing, payment authorization workflow, and the audit-trail capture that a state board or FDA would ask for. The ten-percent layer is the specific judgment calls, the custom-formulation translations, and the regulatory edge-case calls that today live in one or two people's heads.
The order ledger, batch records, COA repository, HCP-license database, and shipment-confirmation logs. Postgres and tested rules outperform anything dressed up as AI here. Most documentation infrastructure already lives in this layer or should.
HCP licensure verification against state-board APIs, prescriber DEA validation, formulary-intake routing, payment authorization, batch-to-shipment matching, audit-trail assembly. Predictable, debuggable, auditable systems. Most operational improvement lives here for a year before any LLM gets the credit.
Custom-formulation request intake that translates an HCP brief into a structured manufacturing spec. Edge-case routing on regulatory adjacency (Schedule II precursors, controlled-substance-adjacent formulations). The judgment calls that today live in one or two operators' heads. This is where methodology pays back across a pivot.
Same sixty-thirty-ten read, applied across the surfaces where a B2B peptide operator makes or loses leverage. The point is that one methodology gives every state expansion, every product addition, and every new operator a shared substrate. Phase one proves it on one surface. Each subsequent phase adapts the same spine.
Inbound HCP customer requests routed through agent-assisted licensure validation against state-board records, prescriber DEA verification where applicable, and a captured audit trail that ties the verification result to every downstream order. The methodology layer is the shared substrate. The operating layer stays on whatever CRM and ERP the firm already runs.
The largest variable in custom peptide work is the spread between a tightly-specified intake brief and an underspecified one. The methodology answer is encoding what a careful intake operator actually asks (peptide identity, target purity, route, regulatory edge-case flags, partner-facility routing), then building the intake layer around that substrate. Every new product line and every state expansion inherits the same intake spine.
Sophisticated downstream buyers (503A pharmacies, 503B facilities, credentialed clinics) pre-qualify suppliers on documentation. The methodology layer makes that documentation assemble in minutes rather than days. COAs, partner-facility attestations, batch-record provenance, HCP-verification logs, and shipment confirmations are surfaced as a single audit packet on demand.
The 2026 rulemaking will redraw which peptides a non-503B channel can lead with. The firms that survive will have a methodology layer that is product-agnostic. Same intake spine, same verification logic, same audit-trail layer, swapped product mix. The methodology is the asset that travels through the pivot.
VigilOre is a multi-agent platform Eduba helped design for compliance work in a regulated extractive industry. The brief: take a documentation-heavy regulatory cycle that consumed more than a hundred sixty hours of human effort, and compress it to a process the operating team could run in minutes. The architecture separated the deterministic-rules layer from the agentic judgment layer (the same sixty-thirty-ten frame in this read), captured the human judgment calls as encoded methodology, and routed everything through an audit-ready trail.
Secondary anchors on the proof shelf. KPMG UK, one of the Big Four, where forty-plus executives were trained inside a top-tier professional-services firm on the same methodology. Correlation One at Pacific Life and Colgate-Palmolive, where 1,500-plus people have been trained since May 2025 with 95 percent thirty-day adoption. Different verticals, same methodology, same evidence the substrate travels into regulated, awards-heavy organizations.
Ethics Engine is a psychometric assessment tool for evaluating ideological and moral patterns in language models. It is the paper a state board, an FDA reviewer, or a credentialed downstream buyer would ask about. Open source, MIT-equivalent license, peer-reviewed paper on arXiv.
Repogithub.com/RinDig/AuditEngine
Interpretable Context Methodology: Folder Structure as Agent Architecture. Submitted to ACM Transactions on Interactive Intelligent Systems. The core claim is that agent context can be organized as a layered filesystem with measurable gains in interpretability and reproducibility. It reads like plumbing because it is plumbing. Open source under MIT license. A fifty-two-member practitioner community has been running on the substrate.
Repogithub.com/RinDig/Interpretable-Context-Methodology-ICM-
Methodology partnerships work when the substrate gets installed once and travels everywhere afterward. The first conversation is half a day with the founder on the post-2025 environment and the methodology layer behind a B2B peptide channel that survives it. The next move is one tightly-scoped pilot. Year two is the engagement that scales with the firm's pivot.
Half-day session on the post-2025 GLP-1 environment, the methodology layer behind the trust assets a regulated B2B channel needs, and the categories worth anchoring around. No deck dump. No vendor pitch. A read on the next twelve months specific to your channel.
One tightly-scoped pilot on the audit-trail surface. HCP-verification logs, COA repository, partner-facility attestations, batch-to-shipment provenance, all assembled into a single audit packet on demand. Outcome is measurable assembly time, before and after.
The substrate from the pilot ported across product lines and state expansions. Same spine, every product. The methodology partner travels with the firm as it pivots out of the GLP-1 lead and into the next product mix.
Annual methodology retainer scoped to scale with product additions and state expansions. Quarterly methodology reviews. Brand and operating execution stay with the firm. NLP Logix invoked as needed for production data work below the methodology layer.
Bring one part of the next-twelve-months question that is keeping the team up. The semaglutide pivot, the audit-trail gap, the cGMP partner question, the next product line. We will map where the methodology layer compresses it. If anything in this read lands wrong, mark it up and bring it to the call. The point is the conversation, not the polish.
Or write directly. thecro@eduba.io · calendly.com/thecro-eduba/30min